Drug Makers Stocks on Investors' Radar -- Amarin, Depomed, DURECT, and Biodel
NEW YORK, November 7, 2016 /PRNewswire/ --
Last Friday, benchmark US indices extended their bearish trend as the NASDAQ Composite ended the trading session down 0.24%; the Dow Jones Industrial Average edged 0.24% lower; and the S&P 500 closed down 0.17%. As the US markets continue to perform mostly in red, stock-Callers.com this morning reviews these four Drug Makers' stocks: Amarin Corporation PLC (NASDAQ: AMRN), Depomed Inc. (NASDAQ: DEPO), DURECT Corporation (NASDAQ: DRRX), and Biodel Inc. (NASDAQ: BIOD). Learn more about these stocks by accessing their free research reports at:
Dublin, Ireland-based Amarin Corp. PLC's stock finished Friday's session 2.18% higher at $2.81 with a total trading volume of 2.07 million shares. Shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have surged 41.92% in the past one year. The Company's shares are trading above its 200-day moving average by 26.40%. Amarin's stock has a Relative Strength Index (RSI) of 36.21.
On October 19th, 2016, research firm Citigroup initiated a 'Buy' rating on the Company's stock, issuing a target price of $5 per share. Free research report on AMRN is available at:
On Friday, shares in Newark, California headquartered Depomed Inc. recorded a trading volume of 5.57 million shares, which was higher than their three months average volume of 1.47 million shares. The stock ended the day 3.85% higher at $22.66. Depomed's stock has advanced 6.74% in the previous three months and 23.89% in the past one year. The Company is trading above its 200-day moving average by 18.61%. Furthermore, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have an RSI of 44.19. The complimentary research report on DEPO can be downloaded at:
Cupertino, California headquartered DURECT Corp.'s stock edged 0.89% higher, to close the day at $1.13. The stock recorded a trading volume of 495,867 shares. Shares of the Company, which researches and develops therapies based on its epigenomic regulator program and proprietary drug delivery platforms, are trading 20.75% and 17.88% below its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 38.31. Visit us today and access our complete research report on DRRX at:
On November 3, 2016, shares in Danbury, Connecticut headquartered Biodel Inc. ended the session at $0.65, up 6.6% from the prior trading session. Biodel Inc.'s shares have surged 12.07% in the last one month, 58.54% in the previous three months, and 80.56% in the past one year. The stock is trading 26.12% above its 50-day moving average and 66.62% above its 200-day moving average. Moreover, shares of the Company, which focuses on the development and commercialization of treatments for diabetes in the US, have an RSI of 56.58. After the completion of the share exchange transaction between Biodel Inc. and Albireo Limited on November 3, 2016, the combined organization - Albireo Pharma, Inc. commenced trading on The NASDAQ Capital Market under the symbol "ALBO", effective November 4, 2016. Get free access to your research report on BIOD at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA